Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

June 28, 2019

Study Completion Date

February 28, 2020

Conditions
Triple-Negative Breast NeoplasmsBreast NeoplasmBreast CancerTriple-Negative Breast Cancer
Interventions
DRUG

Trilaciclib

G1T28

DRUG

Gemcitabine

Gemcitabine

DRUG

Carboplatin

Carboplatin

Trial Locations (54)

1000

University Multiprofile Hospital for Active Treatment, Sofia

University Clinic of Radiotherapy and Oncology, Skopje

1330

MHAT for Womens Health - Nadezhda OOD, Sofia

1756

Special Hospital For Active Treatment In Oncology, Sofia

2000

University Medical Centre Maribor, Maribor

7000

Clinical Hospital Dr. Trifun Panovski, Bitola

9000

Multiprofile Hospital for Active Treatment, Varna

10000

"University Hospital Centre Sestre milosrdnice", Zagreb

University Hospital Centre Zagreb, Zagreb

11000

Special Hospital for Internal Diseases , Oncomed, Belgrade

11070

Clinical Hospital Centre Bezanijska Kosa, Oncology Clinic, Belgrade

18000

Clinical Centre Nis, Clinic of Oncology, Niš

21204

The University of Maryland St. Joseph Medical Center, Towson

Oncology Institute of Vojvodina, Clinic for Internal Oncology, Kamenitz

22031

Virginia Cancer Specialists, PC, Fairfax

22908

University of Virginia, Charlottesville

23456

Virginia Oncology Associates, Virginia Beach

27103

Forsyth Memorial Hospital, Novant Health Oncology Specialists, Winston-Salem

28204

Levine Cancer Center, Charlotte

31000

University Hospital Centre Osijek, Osijek

33324

Florida Cancer Research Institute, LLC., Plantation

33401

Florida Cancer Specialists - East (FCS East), West Palm Beach

33612

Moffitt Cancer Center, Tampa

33705

Florida Cancer Specialists - North (FCS North), St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

34000

Center for Oncology and Radiotherapy, Clinical Centre, Kragujevac

37203

Tennessee Oncology, Nashville

37404

Tennessee Oncology, Chattanooga

42000

General Hospital Varaždin, Varaždin

46250

Community Health Network, Indianapolis

60005

Illinois Cancer Specialists, Arlington Heights

64113

Saint Luke's Cancer Institute, Kansas City

75231

Texas Oncology-Dallas Presbyterian Hospital, Austin

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

75701

Tyler Hematology-Oncology, PA, Tyler

75702

Texas Oncology, P.A., Tyler

76022

Texas Oncology, P.A., Bedford

76104

The Center for Cancer and Blood Disorders, Fort Worth

78217

Texas Oncology-San Antonio Northeast, San Antonio

78745

Texas Oncology, P.A., Austin

79902

Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso

80228

Rocky Mountain Cancer Centers, Lakewood

80909

Memorial UC Health, Colorado Springs

83706

Saint Alphonsus Regional Medical Center, Boise

85704

Arizona Oncology Associates, PC - HOPE, Tucson

89128

Comprehensive Cancer Centers of Nevada, Las Vegas

90603

Innovative Clinical Research Institute, Whittier

91505

Disney Family Cancer Center, Burbank

92123

Sharp Clinical Oncology, San Diego

98405

Northwest Medical Specialties, PLLC, Tacoma

21201-1544

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

10 2650

Antwerp University Hospital (UZA), Edegem

974 01

Mammacentrum, Sv.Agáty, Banská Bystrica

040 01

Cancer Institute VOU, Rastislavova, Košice

Sponsors
All Listed Sponsors
lead

G1 Therapeutics, Inc.

INDUSTRY